Oncotarget

Volume 2, Issue 9

September 2011

View Archive »

About The Cover

Wsh mice as a model of vitiligo insufficiency. A vitiligo affected mouse (left) and a Wsh mouse (right). See Katelyn T. Byrne and Mary Jo Turk.

Table of Contents

Editorial Comments

Wiring the oncogenic circuitry: Pin1 unleashes mutant p53

Wiring the oncogenic circuitry: Pin1 unleashes mutant p53

https://doi.org/10.18632/oncotarget.329

Marco Napoli, Javier E. Girardini, Silvano Piazza,  and Giannino Del Sal
654-656
Abstract  |  PDF  |  HTML  |  How to cite

Developing treatment strategies for rare cancers

Developing treatment strategies for rare cancers

https://doi.org/10.18632/oncotarget.334

Jennifer M. Atkinson,  and Richard J. Gilbertson
657
Abstract  |  PDF  |  HTML  |  How to cite

Research Papers

Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1

Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1

https://doi.org/10.18632/oncotarget.321

Sally-Anne Heasman, Lyubov Zaitseva, Kristian M. Bowles, Stuart A. Rushworth,  and David J. MacEwan
658-668
Abstract  |  PDF  |  HTML  |  How to cite

Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms

Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms

https://doi.org/10.18632/oncotarget.327

Cheryl M. Koh, Tsuyoshi Iwata, Qizhi Zheng, Carlise Bethel, Srinivasan Yegnasubramanian,  and Angelo M. De Marzo
669-683

Research Perspectives

New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

https://doi.org/10.18632/oncotarget.323

Katelyn T. Byrne,  and Mary Jo Turk
684-694
Abstract  |  PDF  |  HTML  |  How to cite

NUAK2: an emerging acral melanoma oncogene

NUAK2: an emerging acral melanoma oncogene

https://doi.org/10.18632/oncotarget.325

Takeshi Namiki, Sergio G. Coelho,  and Vincent J. Hearing
695-704
Abstract  |  PDF  |  HTML  |  How to cite

Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis

Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis

https://doi.org/10.18632/oncotarget.328

Margit Rosner, Helmut Dolznig, Katharina Schipany, Mario Mikula, Oliver Brandau,  and Markus Hengstschläger
705-712
Abstract  |  PDF  |  HTML  |  How to cite

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy

https://doi.org/10.18632/oncotarget.333

Jean-Claude Chomel,  and Ali G. Turhan
713-727
Abstract  |  PDF  |  HTML  |  How to cite

Methodological Reports

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers

https://doi.org/10.18632/oncotarget.313

Benjamin R. Waterhouse, Merel Gijsen, Paul R. Barber, Iain D.C. Tullis, Borivoj Vojnovic,  and Anthony Kong
728-736
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  How to cite


Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC